Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/ijc.IJC_16_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RANK/RANKL Signaling Pathway in Breast Development and Cancer.
Adv Exp Med Biol
January 2025
Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
RANK pathway has attracted increasing interest as a promising target in breast cancer, given the availability of denosumab, an anti-RANKL drug. RANK signaling mediates progesterone-driven regulation of mammary gland development and favors breast cancer initiation by controlling mammary cell proliferation and stem cell fate. RANK activation promotes luminal mammary epithelial cell senescence, acting as an initial barrier to tumorigenesis but ultimately facilitating tumor progression and metastasis.
View Article and Find Full Text PDFMedication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.
J Bone Oncol
February 2025
Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.
Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.
View Article and Find Full Text PDFImmunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments.
Pharmaceuticals (Basel)
November 2024
Department of Anatomy and Genetics, College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
Bone metastases are a prevalent complication in advanced cancers, particularly in breast, prostate, and lung cancers, and are associated with severe skeletal-related events (SREs), including fractures, spinal cord compression, and debilitating pain. Conventional bone-targeted treatments like bisphosphonates and RANKL inhibitors (denosumab) reduce osteoclast-mediated bone resorption but do not directly impact tumor progression within the bone. This review focuses on examining the growing potential of immunotherapy in targeting the unique challenges posed by bone metastases.
View Article and Find Full Text PDF[A Case of Breast Cancer Recurrence 32 Years after Primary Surgery].
Gan To Kagaku Ryoho
December 2024
Dept. of Surgery, Kikkoman General Hospital.
Article Synopsis
- An 80-year-old woman with a history of breast cancer presented with bloody sputum and multiple lung nodules, diagnosed as metastases through a biopsy.
- Initial treatment with denosumab and an aromatase inhibitor led to a 3-year period of tumor shrinkage, followed by regrowth of peritoneal metastases.
- After experiencing severe side effects from second-line chemotherapy, fulvestrant was administered, resulting in long-term tumor shrinkage without negatively impacting her quality of life; this case highlights a rare recurrence of breast cancer 32 years post-surgery.
Invasive cervical root resorption in a cancer patient: A rare case report with 2 years of follow-up and literature review.
Spec Care Dentist
December 2024
Department of Stomatology, School of Dentistry, University of São Paulo, São Paulo, Brazil.
Introduction: Cases involving invasive cervical root resorption (ICRR) in oncological patients are rare, in addition, follow-up of these patients has not yet been reported in the literature.
Objective: This study aims to present a literature review and report a case of denosumab as a possible cause of ICRR in a patient with breast cancer with 2 years of follow-up.
Case Report: A 39-year-old female with a history of luminal breast cancer was treated with denosumab semiannually for osteopenia with discontinuation 1 year ago.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!